MedImmune executive Bahija Jallal will be the new chief of the Gaithersburg biotech under a leadership shuffle by parent company AstraZeneca, a spokesman confirmed Wednesday. Current MedImmune President Peter Greenleaf will lead AstraZeneca’s Latin American business.
Jallal, who joined MedImmune in 2006 as a vice president of translational sciences, has also been promoted to AstraZeneca’s senior executive team, according to an announcement on Tuesday. That announcement, however, left unclear exactly how her role at MedImmune would change, and how that change would affect Greenleaf.
{iframe}http://www.bizjournals.com/baltimore/news/2013/01/16/bahija-jallal-to-replace-peter.html?ana=e_du_pub&s=article_du&ed=2013-01-16{/iframe}